ClinicalTrials.gg

Program

ABBV-722

A development code.

In AbbVie's pipeline, LPAR1. Its studies are mostly in Scleroderma, Systemic · Arthritis, Rheumatoid, led by AbbVie.

Furthest: phase 3, since Oct 23, 20268 company-led studies, 2 open or runningNext primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie82 open or runningphase 3since Oct 23, 2026Oct 29, 2024Jul 2029phase 2 · NCT07904754
  • Named in AbbVie’s own pipeline as ABBV-722, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2024First study: phase 1 study in Healthy VolunteerFirst studyNCT06673238 · 95 enrolled · United States
  2. Jan 15, 2026Phase 1 study in Healthy VolunteersNCT07361367 · 11 enrolled · United States
  3. Feb 17, 2026Phase 1 study in Healthy VolunteerNCT07425899 · 16 enrolled · United States
  4. Mar 26, 2026Phase 1 study in Healthy VolunteerNCT07502417 · 15 enrolled · United States
  5. Apr 28, 2026Phase 1 study in Healthy VolunteersNCT07567781 · 12 enrolled · United States
  6. May 7, 2026Phase 1 study in Healthy VolunteersNCT07599761 · 12 enrolled · United States
  7. Oct 23, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedNCT07933211 · 580 planned
  8. Oct 23, 2026Phase 2 study in Arthritis, RheumatoidNCT07904754 · 250 planned

Ahead

  1. Jul 2029Primary completion: phase 2 study in Arthritis, RheumatoidNCT07904754
  2. Jun 2035Primary completion: phase 3 study in Scleroderma, SystemicNCT07933211

TargetBeta

“LPAR1”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933211Scleroderma, Systemic3Not yet recruitingJun 2035580
NCT07904754Arthritis, Rheumatoid2Not yet recruitingJul 2029250
NCT07599761Healthy Volunteers · United States1CompletedSep 3, 202612
NCT07567781Healthy Volunteers · United States1CompletedJul 21, 202612
NCT07502417Healthy Volunteer · United States1CompletedJul 2, 202615
NCT07425899Healthy Volunteer · United States1CompletedJun 5, 202616
NCT07361367Healthy Volunteers · United States1CompletedMar 23, 202611
NCT06673238Healthy Volunteer · United States1CompletedJun 25, 202695

How it is read

Names in the registry

  • “ABBV-722”, 8 entries

Codes read as this program: ABBV722.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.